Harrow (HROW): 10% owner sold ~$462K

~$462K

Approx. value · 15K sh @ $30.37

105K

Holds after · shares reported

Traded

Jun 9, 2025

Filed

Jun 11, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 18, 2025Insider10% owner sold ~$148K of HROW shares in the open market
2. Mar 24, 2025Insider10% owner sold ~$150K of HROW shares in the open market
3. May 12, 2025Insider10% owner sold ~$259K of HROW shares in the open market
4. May 13, 2025Insider10% owner sold ~$133K of HROW shares in the open market
5. Jun 3, 2025Insider10% owner sold ~$90K of HROW shares in the open market
6. Jun 4, 2025Insider10% owner sold ~$54K of HROW shares in the open market
7. Jun 9, 2025 · this disclosureInsider10% owner sold ~$462K of HROW shares in the open market

What came next

1. Jun 10, 2025Insider10% owner sold ~$462K of HROW shares in the open market
2. Sep 5, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
3. Sep 8, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
4. Sep 17, 2025Company filing · Form 8-K · Auditor changeChanged its auditor“On September 17, 2025, Harrow, Inc. (the “ Company ”), through action of the Audit Committee (the “ Audit Committee ”) of the Company’s Board of Directors, dismissed Crowe LLP (“ Crowe ”) as the Company’s independent registered public accounting firm, effective immediately.”
5. Sep 24, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
6. Sep 26, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
7. Oct 6, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx, LLC and certain affiliated entities, each of which is a wholly owned subsidiary of Harrow, Inc. (the “Company”), effective that date.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Harrow

For Harrow, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HROW page.

Other recent filings by Opaleye Management Inc., 10% owner

• SEC Form 4 at Grace Therapeutics (GRCE)Nov 6, 2026
• SEC Form 4 at Grace Therapeutics (GRCE)Nov 6, 2026
• SEC Form 4 at Grace Therapeutics (GRCE)Nov 6, 2026
• SEC Form 4 at Grace Therapeutics (GRCE)Oct 26, 2026
• SEC Form 4 at Alpha Cognition (ACOG)Oct 26, 2026

The full history of Opaleye Management Inc., 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Harrow

• SEC Form 13F-HRNov 13, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 12, 2026
• SEC Form 13F-HRFeb 9, 2026
• SEC Form 13F-HRNov 14, 2025

Everything OQRO holds on this company is on its HROW page.